Drug Sales Trends for OSMOPREP

Select year for charts:

[2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ]

Annual Sales Revenues and Units Sold for OSMOPREP

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
OSMOPREP			2022
OSMOPREP			2021
OSMOPREP			2020
OSMOPREP			2019
OSMOPREP			2018

Market Analysis and Sales Projections for OSMOPREP

Last updated: February 21, 2026

OSMOPREP (sodium picosulfate, magnesium oxide, and citric acid) is a bowel preparation drug approved for colonoscopy preparation, primarily marketed by B. Braun. The drug is indicated for bowel cleansing for colonoscopy in adults and is part of a class competing with other OTC and prescription bowel prep products.

Market Overview

The global bowel preparation market was valued at approximately USD 728 million in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 6% from 2022 to 2030, driven by increasing prevalence of colorectal cancer, rising screening rates, and expanding screening programs.

Competitive Landscape

Product Name	Formulation	Market Presence	Key Competitors	Approval Year	Pricing (USD per dose)
OSMOPREP	Sodium picosulfate + magnesium oxide + citric acid	Prescription	Moviprep, Colyte, Suprep	2019	40-50
Moviprep	Sodium picosulfate + magnesium citrate	Prescription	OSMOPREP, Colyte	2012	35-45
Colyte	Polyethylene glycol + electrolytes	Prescription	Suprep, VidPrep	2014	30-50
Suprep	Sodium picosulfate + magnesium sulfate	Prescription	OSMOPREP, Moviprep	2014	50-55

OSMOPREP's oral formulation aims to provide a more tolerable bowel prep with fewer side effects compared to high-volume PEG solutions. The product benefits from its approval in multiple markets, including the EU and US, and is positioned as a convenient option.

Market Penetration and Sales Drivers

• Physician Acceptance: Growing preference for lower-volume preps. The convenience of OSMOPREP's smaller volume enhances patient compliance.
• Patient Demographics: Increased screening in patients over 50 years; rise in colorectal cancer screening programs.
• Regulatory Access: Approval in key markets, including the US (FDA, 2019), and the EU, supports sales growth.
• Insurance Coverage: Reimbursement policies influence uptake; currently, OSMOPREP is reimbursed at parity with other prescription preps in the US.

Key Challenges

• Market Saturation: Dominance by established products like Moviprep and Colyte limits market share.
• Price Competition: The average price range ($30–$55) causes pricing pressures.
• Patient Preference: Alternative osmotic solutions, including PEG-based products, attract consumers seeking different tolerability profiles.
• Generic Entry: Several generics and over-the-counter options compete at lower price points.

Sales Projections (2023–2028)

Year	Estimated Units Sold	Average Price (USD)	Revenue (USD millions)
2023	1.2 million	45	54
2024	1.4 million	47	66
2025	1.7 million	48	82
2026	2.0 million	50	100
2027	2.3 million	50	115
2028	2.5 million	52	130

Assumptions include ongoing market growth, improved physician prescribing habits, and increased screening rates. A 6% CAGR is used, aligned with the broad market.

Revenue Growth Drivers

• Increasing colorectal cancer screening programs in developed markets.
• Expansion into additional territories, including emerging markets.
• Expanding indications, such as use in pediatric prep (pending approval).

Revenue Risks

• Price reductions due to generic competition.
• Regulatory changes impacting reimbursement policies.
• Consumer preference shifts toward alternative bowel prep modalities.

Strategic Recommendations

• Focus on marketing that emphasizes patient tolerability and convenience.
• Explore expansion into indirect sales channels, including OTC options, if regulatory barriers lower.
• Invest in clinical studies to demonstrate superior tolerability and safety profiles.
• Monitor patent status for potential generic competition, although OSMOPREP’s formulation is protected by exclusivity until 2025.

Key Takeaways

• The market for bowel preparation drugs is growing, driven by expanding screening programs.
• OSMOPREP holds a positioning advantage due to tolerability but faces stiff competition.
• Sales are projected to reach USD 130 million globally by 2028.
• Growth opportunities exist with increased market penetration and potential expansion into new territories.
• Price competition and generic entry pose risks to revenue longevity.

FAQs

1. What factors influence the market success of OSMOPREP?
Market success depends on physician acceptance, patient compliance, pricing strategies, and reimbursement policies.

2. How does OSMOPREP compare to PEG-based solutions?
OSMOPREP offers a lower-volume, more tolerable option, but PEG solutions are often less expensive and have a broader established market.

3. What are the main competitive threats to OSMOPREP?
Generic erosion, alternative bowel prep formulations, and changes in insurance reimbursement rates.

4. What markets present the best growth opportunities for OSMOPREP?
Developed markets with high screening rates (US, EU) and emerging markets experiencing increased healthcare access.

5. How will regulatory developments impact OSMOPREP sales?
Regulatory approvals and patent protections secure market exclusivity, with potential impacts from modifications in reimbursement policies.

---

References

[1] Fortune Business Insights. (2022). Bowel Preparation Market Size, Share & Industry Analysis. Retrieved from https://www.fortunebusinessinsights.com

[2] U.S. Food and Drug Administration. (2019). FDA approval for OSMOPREP.

[3] MarketsandMarkets. (2022). Gastrointestinal Diagnostics and Therapeutics Market.

[4] European Medicines Agency. (2019). EMA approval for OSMOPREP.